CGX-195 / Congruence Therapeutics - LARVOL DELTA

Congruence Therapeutics…announced an oral presentation at the European Respiratory Society (ERS) Alpha-1 Antitrypsin Conference 2026, held in collaboration with the European Alpha-1 Research Collaboration (EARCO), October 23–24, 2026, in Barcelona, Spain (PRNewswire) - "Congruence scientists will present preclinical data on CGX-195 (CO-8195), the Company's novel, orally active small molecule corrector for alpha-1 antitrypsin deficiency (AATD), describing the activity of CGX-195 in cellular assays and in the PiZ transgenic mouse model of AATD. CGX-195 increased levels of functional, secreted Z-A1AT and reduced levels of polymerized Z-A1AT, which the Company believes addresses AATD at its root cause."

Preclinical • Alpha-1 Antitrypsin Deficiency